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Objectives: To assess the prevalence of inflammation in subjects with chronic painful knee osteoarthritis
(OA), as determined by the presence of synovitis or joint effusion at ultrasonography (US); and to evaluate
the correlation between synovitis, effusion, and clinical parameters.
Methods: A cross sectional, multicentre, European study was conducted under the umbrella of EULAR-
ESCISIT. Subjects had primary chronic knee OA (ACR criteria) with pain during physical activity >30 mm
for at least 48 hours. Clinical parameters were collected by a rheumatologist and an US examination of
the painful knee was performed by a radiologist or rheumatologist within 72 hours of the clinical
examination. Ultrasonographic synovitis was defined as synovial thickness >4 mm and diffuse or nodular
appearance, and a joint effusion was defined as effusion depth >4 mm.
Results: 600 patients with painful knee OA were analysed. At US 16 (2.7%) had synovitis alone, 85
(14.2%) had both synovitis and effusion, 177 (29.5%) had joint effusion alone, and 322 (53.7%) had no
inflammation according to the definitions employed. Multivariate analysis showed that inflammation seen
by US correlated statistically with advanced radiographic disease (Kellgren-Lawrence grade >3; odds
ratio (OR) = 2.20 and 1.91 for synovitis and joint effusion, respectively), and with clinical signs and
symptoms suggestive of an inflammatory ‘‘flare’’, such as joint effusion on clinical examination (OR=1.97
and 2.70 for synovitis and joint effusion, respectively) or sudden aggravation of knee pain (OR=1.77 for
joint effusion).
Conclusion: US can detect synovial inflammation and effusion in painful knee OA, which correlate
significantly with knee synovitis, effusion, and clinical parameters suggestive of an inflammatory ‘‘flare’’.
P
ain is the predominant feature of clinical knee osteo-
arthritis (OA), but its origin is not clearly established.1 2
Among the different tissues contributing to the sources
of pain, synovial tissue or subchondral bone, or both, may
have an important role.3–6 It has been assumed that pain and
functional impairment associated with a clinical ‘‘flare’’ of
OA are also associated with inflammation of synovial tissue.
Several arthroscopy studies have shown that synovitis is
common in painful knee OA.7–10 Magnetic resonance imaging
(MRI) has been validated in the detection of synovitis in
OA,11 and an association between pain and synovial thicken-
ing and effusions detected by MRI has been reported.12
A link between synovial inflammation and progression of
structural damage has been suggested by a number of
studies. A 1 year longitudinal study demonstrated that a
larger volume of effusion aspirations for painful OA knee
predicted OA progression as defined by increased joint space
narrowing.10 Arthroscopic studies have suggested that base-
line synovitis scores predict subsequent worsening of
chondropathy in post-traumatic patellofemoral damage10
and in a large cohort of patients with OA knee.7
The clinical diagnosis of synovial inflammation in knee OA
is empirical and based on the presence of symptoms such as a
sudden change in the level of pain, pain at night, prolonged
morning stiffness, and the presence of an effusion on clinical
examination. However, there are no validated clinical
algorithms available.3 4 Indeed there are limited data from
large cohorts on the prevalence of synovial hypertrophy and
effusions in knee OA, making it difficult to understand their
true association with knee symptoms and examination
findings.
A more objective assessment of inflammatory findings in
OA might be obtained by imaging techniques such as
arthroscopy, MRI, or ultrasonography (US).13 US is non-
invasive and is more easily used in the evaluation of a large
cohort than other imaging modalities. Currently, US seems
more useful in the evaluation of joint effusion and synovitis
(both hypertrophy and morphology)14–17 than in cartilage
examination (although cartilage assessment may be
obtained, especially in the patellofemoral compartment).15 16
It has been demonstrated that US is a valid and reliable
instrument for the assessment of synovial disease, with
results comparable to those obtained by MRI or arthroscopy,
or both.14 18 19
US features were used as the ‘‘gold standard’’, and this
study aimed at assessing the prevalence of inflammation, as
defined by the presence of synovitis and effusion, in subjects
with chronic primary, painful, knee OA. We also evaluated
the correlation between US synovitis and joint effusion, and
between these two variables and clinical features.
Abbreviations: K&L, Kellgren and Lawrence; MRI, magnetic resonance
imaging; OA, osteoarthritis; US, ultrasonography; VAS, visual analogue






This was a cross sectional, multicentre, prospective European
study conducted under the umbrella of the European League
Against Rheumatism (EULAR) Standing Committee for
International Clinical Studies Including Therapeutics Trials
(ESCISIT). Appropriate ethics committee permission was
obtained in each country, and written informed consent was
obtained from every patient before study participation.
Outpatients with chronic, painful, primary knee OA from
seven European countries (Belgium, France, Germany, Italy,
Spain, Switzerland, and the United Kingdom) were recruited
by 50 rheumatologists who performed the clinical examina-
tion. A total of 29 investigators (radiologists or rheumatol-
ogists) performed the US examination of the knees for each
of the subjects included. Selection of these investigators was
based on their experience with musculoskeletal US.
Subjects were examined only once by each of the
investigators within a maximum 72 hour time interval. To
minimise the risk of bias, the investigator who performed the
US examination was unaware of the clinical results before
performing the examination, but the ultrasonographer was
able to communicate in writing the results of the US
examination to the clinical investigator. Data were recorded
by the investigators on two separate case report forms, and
forwarded to a central data entry and quality control service.
The main inclusion criteria were men or women over
18 years of age with primary knee OA according to the
American College of Rheumatology20; with first OA symp-
toms detected at least 6 months before study entry; with
radiographic evidence of OA for the studied knee defined by
the Kellgren and Lawrence (K&L) grade 1–421 22; and with a
pain intensity during physical activities in the previous
48 hours >30 mm measured on a 100 mm visual analogue
scale (VAS).
Exclusion criteria included disabling OA and/or subjects
with grade 4 Steinbrocker functional score23; secondary OA as
defined by the Group for the Respect of Ethics and Excellence
in Science (GREES)5; a history of injury to the studied knee
in the 6 months before study entry; joint replacement (partial
or total) or osteotomy of the studied joint; history of
arthroscopy of the studied joint within the previous year;
and an intra-articular injection of steroids given during the
previous 4 weeks and/or an intra-articular injection of
radionuclide given in the 3 months before the start of the
study.
US variables
The sensitivity of power Doppler in detecting synovial
inflammation is highly machine dependent,24 and therefore
we decided to evaluate the synovial membrane using B mode
US only.
At the time of devising this study, no widely agreed,
standardised definitions of US pathological findings, or
widely recommended acquisition protocols, were available.
On US examination, the normal synovial membrane of the
knee appears as a thin echoic layer up to 3 mm thick. Using B
mode US, two main morphological patterns of synovial
inflammation have been described: the first consists of
hypoechoic tissue which is uniformly distributed in the joint
cavity (diffuse appearance), whereas the second also has a
hypoechoic appearance but exhibits a villous pattern (nod-
ular appearance).13 18 19 In studies in which power Doppler
has been used to confirm the presence of vascularisation in
the inflamed synovium, these two patterns were consistently
found.13 18 19 We therefore produced definitions of synovitis
and effusion based on the limited available published
reports13 18 19 and included descriptions of synovial morphol-
ogy. We employed a conservative ‘‘cut off point’’ for
pathological dimensions reflecting synovial hypertrophy and
effusion. Recommendations for acquisition were also based
on previous reports.25 26
Synovitis and effusion were measured and recorded only in
the suprapatellar recess using US equipment with a high
frequency linear array (minimum 10 MHz). The maximal
synovial thickness and effusion depth were measured in
millimetres using the longitudinal axis.
Synovitis was defined as hypoechoic synovial hypertrophy
with thickness >4 mm and diffuse or nodular appearance,
with the knee semiflexed at 45 ,˚ on the median longitudinal
plane crossing the quadriceps tendon. This definition was
used as the primary outcome. For this study and the
remainder of this paper, the term ‘‘synovitis’’ refers to the
presence of a hypoechoic, hypertrophic synovium. The
presence of a hyperechoic area (for example, fibrous
synovitis) in the joint space was not recorded. It was also
decided not to regard synovial hypertrophy with a normal (as
distinct from hypoechoic) appearance as synovitis, regardless
of the thickness. The morphology of inflammatory synovitis
was evaluated on a three point categorical scale as absent,
nodular, or diffuse.
Joint effusion was defined as an anechoic area and was
measured in the suprapatella recess, with the leg in full
extension, and measured at the maximal depth observed
with a longitudinal scan. It was recorded as absent if the
effusion depth was ,4 mm, and present if >4 mm; this
definition was used as the key secondary outcome.
To standardise the techniques and ensure the highest
possible reproducibility, we performed a 1 day training
session for the ultrasonographers before the start of the
study. The object of this session was to standardise the US
examination (transducer orientation, documentation, posi-
tioning, and adherence to standard planes) with respect to
the recommended acquisition protocol and pathological
definitions. At this training session, all ultrasonographers
separately examined two subjects with painful knee OA.
Clinical parameters
The clinical parameters collected were demographic data,
knee OA characteristics such as disease duration, and OA
localisation (medial femorotibial, lateral femorotibial, or
femoropatellar) and radiological severity based on the K&L
grade for each compartment.22 23 The clinical severity of the
studied knee during the previous 48 hours was also recorded.
This included the patient’s global assessment of knee pain
using a 100 mm VAS,27 the patient’s global assessment of
clinical knee OA severity (100 mm VAS),27 the physician’s
global assessment of clinical knee OA severity (100 mm
VAS),27 the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain subscale (five items and
overall score (100 mm VAS)),28 the WOMAC stiffness
subscale (two items and overall score (100 mm VAS)),28 the
WOMAC physical function subscale (17 items and overall
Table 1 Number (%) of enrolled and analysed





(n = 643) (n = 600)
Belgium 26 (4.0) 26 (4.3)
France 250 (38.9) 224 (37.3)
Germany 35 (5.4) 30 (5.0)
Italy 102 (15.9) 102 (17.0)
Spain 83 (12.9) 80 (13.3)
Switzerland 68 (10.6) 62 (10.3)
United Kingdom 79 (12.3) 76 (12.7)
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score (100 mm VAS)),28 the duration of morning stiffness in
minutes26; awakenings at night due to knee pain29 30 using a
four point verbal scale (no discomfort/no pain; minimal
discomfort, intermittent pain/numbness; severe discomfort,
intermittent or continuous pain resulting in awakening at
night; very severe discomfort, continuous pain preventing
sleep); sudden aggravation of knee pain in the previous
2 weeks on a five point verbal scale (not at all, minimal,
moderate, severe, very severe); and knee joint effusion at
clinical examination, on a four point verbal scale (not at all,
minimal, moderate, important). We also recorded the
previous (during the past 4 weeks) and concomitant sympto-
matic treatments for knee OA.
Statistical analysis
The definitions of confirmed inflammation, according to the
cut off points mentioned above, were used to explore the
relationship between synovitis and/or effusion at US and
clinical parameters.
All collected clinical data were analysed as raw data, or
transformed into binary variables. A composite index of
clinical inflammation was calculated as the presence of at
least two of the following variables: night awakening due to
knee pain, prolonged morning stiffness (>30 minutes),
severe or very severe/sudden aggravation of knee pain in
the previous 2 weeks; and moderate or important joint
effusion at clinical examination.27 For the WOMAC, derived
variables were calculated. For each subscale, the total score
was calculated as the sum of corresponding items (rated on a
VAS). The normalised WOMAC score was calculated based
on a weighted sum of subscale scores. The following weights
were used: 0.20 for the pain subscale, 0.50 for the stiffness
subscale, and 0.059 for the physical function subscale.27 For
continuous data, a one way analysis of variance was used to
make comparisons between groups. For categorical data, a x2
test (Fisher’s exact test, when appropriate) was used.
For nominal data, we used the x2 test with continuity
corrections; for ordinal variables, the Mann-Whitney U test;
and for continuous variables, Student’s unpaired t test.
Pooled or separate variance estimates were used as appro-
priate. All specified analyses were planned to be performed at
the 5% significance level using a two tailed alternative.
The prevalence of knee synovitis and joint effusion was
calculated together with their 95% confidence intervals. To
evaluate the correlation between the presence of knee
synovitis, joint effusion, and clinical parameters of knee
OA, univariate analyses were used to determine the strength
of association between each variable and the primary
outcome and to aid selection of the best variables for the
multivariate analyses.
The appropriate univariate techniques were chosen accord-
ing to the type of data. Those variables found to be strongly
associated with the outcome measure (p,0.20) were
integrated in multivariate analyses. Building of the logistic
regression model proceeded with stepwise selection until no
variables met the criteria for entry (p,0.05) or removal
(p.0.05), for the significance levels of the likelihood ratio
test. All models were adjusted for a country effect. The
same methodology was repeated for joint effusion. Clinical
Table 2 Demographic and clinical characteristics of
subjects with painful knee OA at baseline
Characteristics
Subjects
p Value(n = 600)
Age (years) 66.7 (9.8) 0.0125
Body mass index (kg/m2) 29.9 (5.3) 0.0001
Sex 0.0001
Male, No (%) 165 (27.5)
Female, No (%) 435 (72.5)
Disease duration (years) 6.0 (6.8) 0.1029
K&L radiological grade >3*, No (%) 399 (66.5) 0.0063
Knee pain intensity on VAS 63 (18.5) 0.0001
Joint effusion at clinical examination, No (%) 204 (34.0) 0.0001
Sudden aggravation of knee pain in previous
2 weeks, No (%)
107 (17.8) 0.0001
Duration of morning stiffness (min):
on VAS 13.9 (17.9) 0.5603
>30 minutes`, No (%) 100 (16.7) 0.9571
Night awakenings due to knee pain, No (%) 171 (28.5) 0.0438
WOMAC1
Pain subscale (0–100) 51.7 (20.2) 0.0001
Stiffness subscale (0–100) 53.4 (25.3) 0.0001
Physical function subscale (0–100) 52.0 (19.9) 0.0001
Clinical knee OA severity on VAS (0-100)
Patient’s global assessment 64.2 (21.4) 0.0001
Physician’s global assessment 55.8 (19.5) 0.0001
Results are shown as mean (SD) unless indicated otherwise.
*K&L, Kellgren and Lawrence radiological grade >3 observed in both
femorotibial compartments and/or in femoropatellar compartment of the
knee studied; joint effusion was considered as a binary variable:
‘‘present’’ if graded moderate or important, ‘‘absent’’ if graded absent or
minimal; only those subjects with effusion present are included here.
`morning stiffness was also considered as a binary variable: yes, if
>30 minutes and no, if(30 minutes; 1WOMAC, Western Ontario and
McMaster Universities OA Index, Fisher’s exact test for statistically












Figure 1 Synovitis at ultrasonography in subjects with painful knee OA:
distribution of synovial thickness.
Table 3 Prevalence of knee synovitis on ultrasonography




Total number of subjects, No (%) 500 (83.3) 100 (16.7)
Synovial thickness (mm) ,0.0001
Mean (SD) 1.3 (1.5) 5.8 (3.0)
Median (range) 1 (0–19) 5 (4–29)
Appearance of synovial tissue,
No (%)
,0.0001
Absent 278 (55.6) 0 (0)
Nodular 75 (15.0) 56 (56.0)
Diffuse 147 (29.4) 44 (44.0)
Maximal effusion depth (mm) ,0.0001
Mean (SD) 3.4 (4.5) 6.9 (3.9)
Median (range) 2.7 (0–20) 6.1 (0–71)
*Knee synovitis was defined as ‘‘present’’ if synovial thickness was
>4 mm with diffuse or nodular appearance. p Values refer to
comparisons between subgroups with or without synovitis (Student’s t test
for quantitative variables and x2 test for qualitative variables).
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parameters were compared between countries using the
appropriate statistical test. A similar exploratory analysis was
then performed in subgroups of subjects with higher and
advanced radiographic disease (K&L grade >3) or with an
earlier radiographic stage (K&L grade ,3), based on their
predictive factors.
For the primary objective, a sample size of 600 subjects was
required to achieve a precision of ¡2.5–4% for an observed
prevalence ranging between 10% and 30%. With respect to
the secondary objectives, with this sample size, we also had
80% power to detect differences of 10–20% in the proportions
of various clinical characteristics, with an observed preva-
lence ranging between 15% and 30%.31
RESULTS
Demographic and other baseline characteristics
Of 643 subjects enrolled in the study, 627 were potentially
analysable; 16 (2.5%) subjects had only one case report form
available from clinical or US evaluation. Among these 627
subjects, 27 (4.3%) subjects had a major protocol deviation,
leaving 600 subjects who were included in the final analysis.
Table 1 shows the distribution of subjects by country. Table 2
summarises the main baseline characteristics of the 600
analysed subjects. Some statistically significant differences in
the baseline demographic and clinical data between countries
were found (table 2).
Moderate or important knee joint effusion on clinical
examination was present in 34.0% of subjects. When the
inflammation composite score was considered, only 37.3%
had at least two of the four clinical features listed above
(expressed as binary variables). Of the 600 subjects, 410
(68.3%) had recently used or were currently using drugs for
their OA. The different classes of treatments were non-
selective non-steroidal anti-inflammatory drugs in 34.8% of
subjects, selective inhibitors of cyclo-oxygenase-2 in 17.1%,
paracetamol in 23.9%, opioids in 15.6%, and symptomatic
slow acting drugs in 8.5%.
Prevalence of ultrasonographic knee synovitis
In the total group the mean (SD) synovial thickness
measured was 2.1 (2.5) mm, and the median was 1.5 mm
(range 0–29 mm). This distribution was not normal. The
appearance of synovial tissue was recorded as absent,
nodular, or diffuse in 46.3%, 21.8%, and 31.8% of subjects,
respectively (p,0.0001). Figure 1 shows the distribution of
synovial thickness in the overall group. Table 3 shows the
distribution of synovial thickness and appearance as well as
the maximal effusion depth in subjects with or without
synovitis.
Prevalence of ultrasonographic joint effusions
The mean (SD) effusion depth measured in the total group
was 4.0 (4.6) mm, and the median was 3.2 mm (range 0–
71 mm). The distribution of the effusion depth was not
normal.
Figure 2 shows the distribution of effusion depth in the
overall group of patients. Table 4 shows the distribution of
synovial thickness, synovial appearance, and the maximal
effusion depth in subjects with or without effusion.
Relationship between ultrasonographic knee synovitis
and joint effusion
Among subjects with painful knee OA, 322 (53.7%) had
neither US synovitis nor effusion, 177 (29.5%) had effusion
alone, 85 (14.2%) had both synovitis and effusion, and only
16 (2.7%) had synovitis alone. The association between knee
synovitis and joint effusion was highly significant
(p,0.0001). Additionally, a strong relationship between
synovial thickness and effusion depth was demonstrated
using actual measurements rather than the predefined
protocol cut off points (correlation coefficient=0.51,
p,0.0001) (fig 3).
As reported above, 37.3% of subjects had at least two of the
four clinical features suggesting an inflammatory episode. In
this subgroup, only 52.5% subjects had synovitis or effusion,












Figure 2 Effusion depth on ultrasonography in subjects with painful
knee OA: distribution of effusion depth.
Table 4 Prevalence of joint effusion on ultrasonography




Subjects, No (%)` 338 (56.4) 261 (43.6)
Maximal effusion depth (mm) ,0.0001
Mean (SD) 1.3 (1.4) 7.5 (5)
Median (range) 1.2 (0–4) 6.3 (4–71)
Synovial thickness (mm) ,0.0001
Mean (SD) 1.1 (1.5) 3.3 (2.9)
Median (range) 0.6 (0–10.2) 2.9 (0–29)
Appearance of synovial tissue,
No (%)
,0.0001
Normal 231 (68.3) 47 (18.0)
Nodular 34 (10.1) 97 (37.2)
Diffuse 73 (21.6) 117 (44.8)
*Joint effusion was defined as present if depth >4 mm; p values refer to
comparisons between subgroups with or without joint effusion. (Student’s
t test for quantitative variables and x2 test for qualitative variables);

























Figure 3 Relationship between ultrasonography synovial thickness and
effusion depth using linear regression.
1706 D’Agostino, Conaghan, Le Bars, et al
www.annrheumdis.com
Figure 4 shows an example of synovitis (A) and joint
effusion (B) detected by US.
Univariate analysis
Synovitis
For synovitis, the significant variables (p,0.20) arising from
the univariate analysis were sex (p=0.1772), weight
(p=0.1649), height (p=0.1690), K&L radiological grade
>3 observed in both femorotibial compartments (p,0.0001)
or radiological grade >3 observed in all three compartments
of the studied knee (p=0.0017), physician’s global assess-
ment of clinical knee OA severity (p=0.0055), morning
stiffness >30 minutes (p=0.0542), knee joint effusion at
clinical examination (p,0.0001), and sudden aggravation of
knee pain in the previous 2 weeks (p=0.0479).
Joint effusion
For joint effusion, the significant variables (p,0.20) arising
from the univariate analysis were sex (p=0.0016), weight
(p=0.1943), height (p=0.0400), spine osteoarthritis
(p=0.0242), K&L radiological grade >3 observed in both
femorotibial compartments of the studied knee (p,0.0001)
and K&L radiological grade >3 observed in all three
compartments of the studied knee (p=0.0002), physician’s
global assessment of clinical knee OA severity (p=0.0072),
knee joint effusion at clinical examination (p,0.0001),
sudden aggravation of knee pain in the previous 2 weeks
(p=0.0441), and the composite index of inflammation
(p=0.0024). The variables strongly associated with the
outcome measures were integrated in the multivariate
analysis.
Figure 4 Synovitis (A) and joint effusion (B) on US in subjects with painful knee OA. (A) Synovitis in a longitudinal scan (suprapatellar recess). (B) Joint
effusion in a longitudinal scan (suprapatellar recess): S, synovitis; E, effusion.
Table 5 Relationship between knee synovitis or joint effusion on US and predictive
features in subjects with painful knee OA. Summary of multivariate analyses—odds ratio
estimates (adjusted by country)
Predictive factor
US knee synovitis
p Value* OR (95% CI)
Absent Present
No (%) No (%)
Radiological K&L grades`
3–4 260 (77.8) 74 (22.2) ,0.0001 2.20 (1.33 to 3.64)
0–2 240 (90.2) 26 (9.8)
Joint effusion at clinical examination1
Moderate-important 153 (75.0) 51 (25.0) ,0.0001 1.97 (1.19;3.23)
Absent-minimal 347 (87.6) 49 (12.4)
US joint effusion
Sex
Female 262 (60.4) 172 (39.6) 0.0016 0.62 (0.41 to 0.94)
Male 76 (46.1) 89 (53.9)
Radiological K&L grades`
3–4 162 (48.6) 171 (51.4) ,0.0001 1.91 (1.32 to 2.77)
0–2 176 (66.2) 90 (33.8)
Joint effusion at clinical examination1
Moderate-important 93 (45.6) 111 (54.4) 0.0001 2.70 (1.76 to 4.16)
Absent-minimal 245 (62.0) 150 (38.0)
Sudden aggravation of knee pain**
Severe-very severe 143 (52.0) 132 (48.0) 0.0441 1.77 (1.16 to 2.71)
Absent-minimal-moderate 195 (60.2) 129 (39.8)
*p Value of univariate analysis; OR: odds ratio, 95% CI: 95% confidence interval, OR and 95% CI are adjusted
though a logistic regression model analysing the probability of the presence of knee synovitis or joint effusion at
US; `K&L, Kellgren and Lawrence radiological grade >3, or ,3 observed in both femorotibial compartments of
the studied knee; 1joint effusion: absent or minimal versus moderate or important; sex: female versus male;
**sudden aggravation of knee pain in the previous 2 weeks: absent, minimal or moderate versus severe or very
severe.




We found those subjects with knee OA with a more severe
radiological grade (K&L grade >3) and moderate or
important knee joint effusion on clinical examination had
an increased probability of synovitis being detected at US
examination (odds ratio (OR)=2.20 and 1.97, respectively).
Joint effusion
Subjects with knee OA with a more severe radiological grade
(K&L grade >3), sudden aggravation of pain in the previous
2 weeks, and moderate or important knee joint effusion on
clinical examination, had an increased probability of a joint
effusion being detected at US examination (OR=1.91, 2.70,
and 1.77, respectively). Interestingly, women had fewer joint
effusions than men (OR=0.62).
The multivariate analyses for US synovitis and joint
effusion showed similar results when adjusted for country.
Arbitrarily, adjustment for countries was performed using the
United Kingdom as reference estimates. Table 5 presents the
adjusted results.
Note that whatever the definition of US inflammation
(synovitis or effusion), the results of the multivariate analysis
were the same: subjects with knee OA with a more severe
radiological grade (K&L grade >3) and moderate or
important knee joint effusion on clinical examination had
an increased likelihood of inflammation on US examination.
Conversely, those with a lesser degree of radiological damage
and no or mild joint effusion on clinical examination had an
increased probability of no synovitis or effusion being
detected on US examination. A clinical history of no sudden
increase in pain intensity in the previous 2 weeks also
increased the probability of no detectable US effusion.
A multivariate analysis was then conducted separately in
the subgroups of subjects with earlier (K&L score ,3) and
more advanced (K&L >3) radiographic disease, respectively,
in both femorotibial compartments. In subjects with earlier
radiographic stage, the OR of joint effusion at clinical
examination was increased to 4.11 (p=0.003) and 3.42
(p=0.0002) for prediction of US synovitis and joint effusion,
respectively; the OR of sudden aggravation of knee pain in
the previous 2 weeks increased to 3.26 (p=0.0006) for
prediction of US joint effusion; sex was no longer predictive
for inflammation at US examination.
DISCUSSION
This was the first large, multicentre, international study to
examine the prevalence of synovitis and/or joint effusion as
detected by US in subjects with symptomatic, chronic knee
OA. The prevalence of US features suggestive of an
inflammatory process, either synovitis or effusion, was quite
high (47%). A large group of patients also had US detected
effusion and no detectable synovitis (30%). These findings
may reflect the strict definitions of synovitis and effusion
employed in this study; and, possibly, microscopic synovitis
may exist in the absence of US detected synovial hypertro-
phy.
Although it has been shown that US is a useful instrument
for assessing joint effusion and synovitis in inflammatory
rheumatic diseases, its usefulness in OA has not yet been
established, perhaps owing to the limitations of this
technique in evaluating cartilage, the focus of much OA
research.14–16 32 Another reason may be the idea that this
technique is considered too ‘‘operator dependent‘‘. To
examine this problem, and in the absence of agreed
definitions and acquisition protocols for US detected synovial
disease, we established conservative definitions (measure-
ment cut off points) for both synovial thickness and joint
effusion depth; we only measured synovial disease in the
suprapatellar compartment of the knee and used grey scale
US for defining synovitis (instead of Doppler techniques,
which have greater variability between machines and read-
ers). A training session was also used to improve reliability
across the large numbers of centres.
Our results suggest that US inflammation was not detected
in at least half the subjects with chronic, symptomatic knee
OA. We found no correlations between US inflammatory
signs and pain intensity during recent physical activity. One
explanation might be that our study focused on the
assessment of synovial features alone in painful knee OA
and we did not explore other possible sources of pain.
Certainly this supports recent MRI studies, which suggest
that non-synovial features such as bone marrow lesions may
be associated with pain.33
Clinical features were not good predictors of US synovial
disease—even in the third of subjects with two out of four
clinical features considered suggestive of inflammation, only
half had inflammation confirmed at US examination.
Features such as night pain and morning stiffness .30 min-
utes did not correlate with synovitis or joint effusion.
It has been suggested that synovitis and joint effusion are
secondary phenomena in OA as a consequence of chondro-
lysis; and that the inflammatory process, and in particular
the synthesis of matrix degrading enzymes, subsequently
aggravates cartilage breakdown, resulting in an amplifying
cycle and perhaps explaining the more rapid progression of
chondropathy in late stage disease.34 Certainly this study
confirmed the high correlation between the radiographic
stage of OA and the inflammatory process. The presence of
inflammatory signs observed at US was statistically asso-
ciated with advanced radiographic disease as expressed by
high radiological scores (K&L grade 3–4), and at an earlier
stage (K&L grade 1–2) with clinical signs or symptoms
suggestive of an inflammatory flare—for example, severe or
very severe sudden aggravation of pain in the previous
2 weeks, or moderate or marked joint effusion. Note that this
subgroup analysis was exploratory and no definite conclu-
sions can be drawn owing to the small number of subjects.
Conversely, for subjects with painful knee OA and less severe
radiological grade (K&L grade ,3), and with no/minimal
knee joint effusion at clinical examination and sudden
aggravation of pain in the previous 2 weeks, the likelihood
of no US inflammatory features was increased. Moreover, the
use of any drugs was not related to US synovitis or effusion.
There are some limitations to this study. Firstly, some
heterogeneity was found between countries for most of the
characteristics at clinical examination. This may reflect
differences in healthcare systems and thus subject referral.
Also, the distribution of synovial thickness and effusion
depth was not normal, probably owing to a technical
limitation in measuring very small amounts of synovial
tissue or effusion. As mentioned, in order to reduce
interobserver variability, we had a training session before
the study started. However, no formal assessment of
interobserver reliability was made owing to the large number
of ultrasonographers taking part in the study (as commonly
occurs with other studies which use a large number of
examiners performing, for example, swollen joint counts).
Clearly, additional studies in this field need to be performed
to determine standardised definitions and acquisition based
on normal and arthritic cohorts; some of these problems are
currently being examined by a EULAR/OMERACT US work-
ing group.
This study demonstrated that US detected synovitis and
effusion are common in painful knee OA and confirmed
previous reports of the lack of sensitivity of clinical features
in predicting inflammation of the synovium. In particular,
this study clearly emphasises that synovitis is more commonly
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seen in advanced radiographic disease than in early radio-
graphic disease, suggesting that US may be more useful for
detecting inflammation in early OA. Further studies are
required in order to better understand the underlying process
driving OA synovitis and whether this process differs in early
and late disease.
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